MGX 8-K furnishes Q3 2025 results press release and MGX-001 update

Rhea-AI Filing Summary

Metagenomi, Inc. (MGX) filed an 8‑K announcing it furnished a press release with financial results for the quarter ended September 30, 2025 and additional business updates. The company also furnished a separate press release reporting positive dose range finding data from its MGX-001 hemophilia A program, and made its November 2025 corporate presentation available. These materials are furnished, not filed, under the Exchange Act.

Included exhibits are: 99.1 (earnings press release dated November 11, 2025), 99.2 (MGX-001 program update press release dated November 11, 2025), 99.3 (corporate presentation dated November 2025), and 104 (cover page Inline XBRL).

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001785279false00017852792025-11-112025-11-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 11, 2025

Metagenomi, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41949	81-3909017
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
5959 Horton Street 7th Floor
Emeryville, California				94608
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (510) 871-4880

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		MGX		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 2.02 Results of Operations and Financial Condition.

On November 11, 2025, Metagenomi, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2025 and additional business updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02 (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), except as expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

Press Release

On November 11, 2025, the Company issued a press release announcing positive dose range finding data from the Company’s MGX-001 hemophilia A program. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Corporate Presentation

A copy of the Company’s November 2025 corporate presentation is furnished as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in this Item 7.01 (including Exhibits 99.2 and 99.3) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Earnings Press Release Issued by Metagenomi, Inc. on November 11, 2025
99.2		Press Release Issued by Metagenomi, Inc. on November 11, 2025
99.3		Corporate Presentation of Metagenomi, Inc. dated November 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Metagenomi, Inc.
Date:	November 12, 2025	By:	/s/ Jian Irish
			Jian Irish, Ph.D., M.B.A. President and Chief Executive Officer

FAQ

What did Metagenomi (MGX) disclose in this 8-K?

It furnished a press release with results for the quarter ended September 30, 2025, a press release on MGX-001 data, and a November 2025 corporate presentation.

Which 8-K items are included for MGX?

Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).

Are the exhibits considered filed or furnished?

They are furnished and not deemed filed under Section 18 of the Exchange Act.

What exhibits were attached to Metagenomi’s 8-K?

99.1 earnings press release, 99.2 MGX-001 program press release, 99.3 November 2025 corporate presentation, and 104 cover page Inline XBRL.

What program update did MGX announce?

Positive dose range finding data from its MGX-001 hemophilia A program, via a press release furnished as Exhibit 99.2.

What exchange and ticker does Metagenomi use?

Common stock trades on the Nasdaq Global Select Market under ticker MGX.